HBM Holdings Ltd Sustainability Reports
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise engaged in the discovery, development, and commercialization of differentiated antibody therapeutics. The company specializes in creating innovative treatments for immunology and oncology using its proprietary Harbour Mice platform.
Sector: Manufacturing
Country: China
Exchange: Hong Kong Stock Exchange
LEI: 254900ZT5QBQG3JL9J21
FIGI: BBG00Y9WW6P9
10 reports from 2020 to 2025
